As a result, these three proteins were proposed as prognostic biomarkers for GC, while CDC42, NAPA, and ANXA11 remained leading candidates for early-stage diagnosis based on their consistent expression patterns in both urine and tissue (Fan et al., 2022). The gene discussed is NAPA; the disease is gastric cancer.